Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Validation of the Response Speed Rule to Predict the Efficacy of a Therapeutic Regimen in Myeloma

Jose Enrique De La Puerta Rueda, MD, Clara Gómez Pérez, MD, Concepción Velado Rodriguez, Tomas Carrascosa Vallejo, MD, Begoña Sancho Garaizabal, MD, Maria José Ereño Ealo, MD, Elixabete Pastor Ausin, MD, Isabel Uriarte, MD, Iñigo Vicente Olabarria, MD, Alberto Cabrera Zubizarreta, MD, José María Ontañón Garcés, MD, Ibone Saralegui Prieto, MD, Matxalen Olivares Salaverri, MD, Inmaculada Barredo Santamaría, MD, Alberto Sáiz López, MD, Paula Arana Berganza, MD, Natalia Maruri Machado, MD, Raquel Pérez Garay, MD, Eloisa Urrechaga Igartua, MD, Ianire Etxeguren Urkixo, MD, Garazi Letamendi Madariaga, MD, Cristina Martínez Bilbao, MD, Itxaso Amarika Ibarrondo, MD, Amaia Casado Diez, MD, Inés González Vallejo, MD, Cristina Cortes Fernández, MD, Eukene Gainza González, MD, Jesus Ojanguren Bergaz, MD, Paloma Ibarrondo Chamorro, MD, Ane Aranbarri Chamorro, MD, Javier Goikolea Ugarte, Pharm, Miriam Bustos Martínez, Pharm, Amaia Sierra Zabala, Urko Aguirre Larracoechea, Marta Alonso Varela, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-138555

Published: 2020

Journal Articles

Precision Medicine Based on the Achievement of Sustained Undetectable Minimal Residual Disease (MRD) By Next-Generation Flow (NGF) and Imaging Leads to Significant Reduction in Risk of Progression of Patients with Multiple Myeloma (MM)

Jose Enrique De La Puerta Rueda, MD, Leire Burgos, Garazi Letamendi Madariaga, MD, Cristina Martinez Bilbao, MD, Luis Atutxa Aresti, MD, Jesus Ojanguren Bergaz, MD, Matxalen Olivares Salaverri, MD, Begoña Sancho Garaizabal, MD, Isabel Uriarte, MD, Iñigo Vicente Olabarria, MD, Raquel Pérez Garay, MD, Ana de Juan Arroyo, Pharm, Itxaso Amarika Ibarrondo, MD, Tomas Carrascosa Vallejo, MD, Amaia Casado Diez, MD, Cristina Cortes Fernández, MD, Ianire Etxeguren Urkixo, MD, Eukene Gainza González, MD, Inés González Vallejo, MD, Javier Goikolea Ugarte, Pharm, Inmaculada Barredo Santamaría, MD, Alberto Sáiz López, MD, Antonio Vázquez Rodríguez, MD, Eloisa Urrechaga Igartua, MD, Maria José Ereño Ealo, MD, Estibalitz Montejo Rodrigo, MD, Elixabete Pastor Ausin, MD, Alberto Cabrera Zubizarreta, MD, José María Ontañón Garcés, MD, Ibone Saralegui Prieto, MD, Natalia Maruri Machado, MD, Paula Arana Berganza, MD, Mara Celis Alvarez, MD, Ane Aranbarri Larrañaga, MD, Paloma Ibarrondo Chamorro, MD, Bruno Paiva, PhD

Blood (2019) 134 (Supplement_1): 3170.

https://doi.org/10.1182/blood-2019-125062

Published: 2019

Journal Articles

High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM)

Paula Arana, Aintzane Zabaleta, Marta Lasa, Patricia Maiso, PhD, Diego Alignani, Tomas Jelinek, MD, Victor Segura, PhD, Wouter van den Bossche, Cristina Teodosio, Daniela Damasceno, Paula Rodriguez-Otero, MD PhD, Felipe Prosper, MD, Maria-Victoria Mateos, MD PhD, Juan Jose Lahuerta, Joan Bladé, Jacques J.M. van Dongen, MD PhD, Jesus San Miguel, MD PhD, Alberto Orfao, MD PhD, Bruno Paiva, PhD

Blood (2016) 128 (22): 482.

https://doi.org/10.1182/blood.V128.22.482.482

Published: 2016

Journal Articles

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Blood (2016) 127 (25): 3165–3174.

https://doi.org/10.1182/blood-2016-03-705319

Published: 2016

Includes: Supplemental data

Journal Articles

Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials

Blood (2015) 126 (23): 19.

https://doi.org/10.1182/blood.V126.23.19.19

Published: 2015

Journal Articles

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2015) 126 (23): 2963.

https://doi.org/10.1182/blood.V126.23.2963.2963

Published: 2015

Journal Articles

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

Paula Arana, Bruno Paiva, PhD, Noemi Puig, MD PhD, Teresa Cedena, Lourdes Cordon, Maria Belen Vidriales, MD PhD, Joaquin Martinez-López, MDPhD, Enrique M. Ocio, MD PhD, Miguel T Hernandez, Ana Isabel Teruel, MD, Mercedes Gironella, M Asuncion Echeveste, Laura Rosiñol, MDPhD, Rafael Martinez, MDPhD, Albert Oriol, MDPhD, Joan Blade, MDPhD, Juan Jose Lahuerta, Maria-Victoria Mateos, Jesus San Miguel, MDPhD

Blood (2015) 126 (23): 721.

https://doi.org/10.1182/blood.V126.23.721.721

Published: 2015

NARROW

Validation of the Response Speed Rule to Predict the Efficacy of a Therapeutic Regimen in Myeloma

Precision Medicine Based on the Achievement of Sustained Undetectable Minimal Residual Disease (MRD) By Next-Generation Flow (NGF) and Imaging Leads to Significant Reduction in Risk of Progression of Patients with Multiple Myeloma (MM)

High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM)

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

Email alerts

ASH Publications

American Society of Hematology

Validation of the Response Speed Rule to Predict the Efficacy of a Therapeutic Regimen in Myeloma

Precision Medicine Based on the Achievement of Sustained Undetectable Minimal Residual Disease (MRD) By Next-Generation Flow (NGF) and Imaging Leads to Significant Reduction in Risk of Progression of Patients with Multiple Myeloma (MM)

High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM)

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only